Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02221960
Other study ID # D6050C00001
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date September 15, 2014
Est. completion date July 3, 2017

Study information

Verified date March 2019
Source MedImmune LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate MEDI6383 when given alone or together with MEDI4736 in adult subjects with recurrent or metastatic solid tumors.


Description:

This is a Phase 1, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics, and antitumor activity of MEDI6383 alone and in combination with MEDI4736 in adult subjects with recurrent or metastatic solid tumors.


Recruitment information / eligibility

Status Completed
Enrollment 39
Est. completion date July 3, 2017
Est. primary completion date July 3, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria:

1. Male and female subjects; age = 18

2. Written informed consent must be obtained

3. Subjects must meet the following criteria:

1. Have recurrent or metastatic solid tumors

2. Must have received and have progressed, are refractory, or are intolerant to standard therapy appropriate for the specific tumor type. Subjects should not have received more than 5 prior lines of therapy for recurrent or metastatic disease including both standards of care and investigational therapies

4. Subjects must have at least 1 lesion

5. Subjects must consent to provide archived tumor specimens and / or tumor biopsy for correlative biomarker studies.

6. Eastern Cooperative Oncology Group performance score of 0 or 1

7. In the opinion of the invesgator likely to complete = 8 weeks of treatment.

8. Adequate organ function as determined by:

i. Absolute neutrophil count = 1.5 x 109/L (1,500/mm3) ii.Platelet count = 100 x 109/L (100,000/mm3) iii.Hemoglobin = 9.0 g/dL within first 2 weeks prior to first dose of investigational product iv.Calculated creatinine clearance* (CrCl) or 24 hour urine CrCl > 50 mL/min v.Total bilirubin = 1.5× ULN; for subjects with documented/suspected Gilbert's disease, bilirubin = 3× ULN vi.Aspartate transaminase (AST) and alanine transaminase (ALT) = 2.5× ULN vii.Serum Electrolytes within normal limits

9. Females of childbearing potential who are sexually active with a nonsterilized male partner must use 2 methods of highly effective contraception from screening, and must agree to continue using such precautions for 90 days after the final dose of investigational product; 10) Nonsterilized males who are sexually active with a female partner of childbearing potential must use a highly effective method of contraception from Day 1 through 90 days after receipt of the final dose of investigational product

Exclusion Criteria:

1. Prior treatment with TNFRSF agonists including OX40, CD27, CD137 (4-1BB), CD357 (GITR) .

2. Subjects who have received prior therapy with regimens containing CTLA-4, PDL-1, or PD-1 antagonists are NOT permitted to enroll unless all of the following apply:

- Must not have experienced a toxicity that led to permanent discontinuation of prior immunotherapy

- All AEs while receiving prior immunotherapy must have resolved to = Grade 1 or baseline prior to screening for this study.

3. Must not have experienced a = Grade 3 AE or neurologic or ocular AE of any grade while receiving prior immunotherapy

4. History of severe allergic reactions to any unknown allergens or any components of the study drug formulations

5. Active or prior documented autoimmune disease within the past 2 years.

6. Untreated central nervous system metastatic disease l

7. Concurrent enrollment in another clinical study, unless it is an observational (non interventional) clinical study or the follow-up period of an interventional study

8. Receipt of anticancer therapy within 28 days prior to the first dose of Investigational Product

9. Any concurrent chemotherapy, immunotherapy, or biologic or hormonal therapy for cancer treatment.

10. Unresolved toxicities from prior anticancer therapy

11. Systemic anticoagulation or daily aspirin dose exceeding 325 mg per day

12. Current or prior use of immunosuppressive medication within 14 days prior to the first dose of MEDI6383. )

13. History of primary immunodeficiency, solid organ transplantation, or tuberculosis

14. True positive test results for human immunodeficiency virus (HIV) or hepatitis B or C

15. Receipt of live, attenuated vaccine within 28 days prior to the first dose of investigational products )

16. Pregnant or breastfeeding women

17. Major surgery (as defined by the investigator) within 4 weeks prior to first dose of MEDI6383 or still recovering from prior surgery. Local surgery of isolated lesions for palliative intent is acceptable

18. Other invasive malignancy within 2 years

Study Design


Related Conditions & MeSH terms

  • Recurrent or Metastatic Solid Tumors

Intervention

Biological:
MEDI6383
Subjects will receive MEDI6383 until disease progression or adverse event.
MEDI6383 and MEDI4736
Subjects will recieve MEDI6383 and MEDI4736 until disease progression or adverse event.

Locations

Country Name City State
Australia Research Site Parkville
United States Research Site Chicago Illinois
United States Research Site La Jolla California
United States Research Site Nashville Tennessee
United States Research Site New Haven Connecticut
United States Research Site New York New York
United States Research Site Portland Oregon
United States Research Site Washington District of Columbia

Sponsors (1)

Lead Sponsor Collaborator
MedImmune LLC

Countries where clinical trial is conducted

United States,  Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety Primary endpoint will be the number (%) of subjects with adverse events and serious adverse events. From time of informed consent through 12 weeks after last dose of investigational product
Secondary Preliminary Antitumor Activity The endpoints for assessment of antitumor activity include objective response (OR), disease control (DC), duration of response (DoR), progression-free survival (PFS), and 3-year overall survival (OS) Duration of Study
Secondary Pharmacokinetics of MEDI6383 or MEDI6383/MEDI4736 When MEDI6383 is administered alone, the endpoints for assessment of PK of MEDI6383 include individual subject MEDI6383 concentrations in serum at different time points after MEDI6383 administration. When MEDI6383 is administered together with MEDI4736, the endpoints for assessment of PK of MEDI6383 and MEDI4736 include individual subject MEDI6383 and MEDI4736 concentrations in serum at different time points after MEDI6383 and MEDI4736 administration. PK Parameters that may be modeled may include Cmax, Area Under the concentration-time curve, Clearance, and terminal half-live. From time of informed consent through 12 weeks after last dose of investigational product
Secondary Biomarker Activity The endpoints for assessment of pharmacodynamic activity include immunohistochemistry of tumor biopsies and assessment of tumor-infiltrating lymphocyte phenotypic markers From time of informed consent through 12 weeks after last dose of investigational product
Secondary Immunogenicity The endpoint for for the assessment of immunogenicity will include the number and percentage of subjects that develop anti-drug antibodies. From time of informed consent through 12 weeks after last dose of investigational product
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06093698 - An Exploratory Study of A-337 in the Management of Malignant Solid Dose Escalation and Expansion Phases Phase 1
Recruiting NCT06330064 - A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXD) In Subjects With Recurrent Or Metastatic Solid Tumors Phase 2